Search
Palmoplantar keratoderma
go.drugbank.com/conditions/DBCOND0020029Drugs: Salicylic acidSynonyms: Hyperkeratosis of palms and solesLusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalLusutrombopag is currently in phase III development in various European countries including Austria, Belgium, Germany, and the UK [A36730]. … Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan).
Categories: Blood and Blood Forming OrgansGremlin-1
go.drugbank.com/bio_entities/BE0011799TargetHumansCan inhibit the growth or viability of normal cells but not transformed cells when is overexpressed (By similarity) … Cytokine that may play an important role during carcinogenesis and metanephric kidney organogenesis, as a BMP antagonist required for early limb outgrowth and patterning in maintaining the FGF4-SHH feedback
Synonyms: Increased in high glucose protein 2, Down-regulated in Mos-transformed cells proteinTriethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigational[A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and … TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925.
Categories: Compounds used in a research, industrial, or household setting, Alimentary Tract and MetabolismEtafedrine
go.drugbank.com/drugs/DB11587ApprovedEtafedrine (INN) or ethylephedrine is a long-acting bronchodilator and has been an ingredient combined with other drugs in the brand names Nethaprin [A32757] and Dalmacol [L2568]. … It was previously available as both the free base and as the hydrochloride salt manufactured by Sanofi-Aventis (now Sanofi) has been discontinued [L2563].
Capivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalThis approval is based on favorable results obtained from the CAPItello-291 trial, where the combination of capivasertib and [fulvestrant] reduced the risk of disease progression or death by 50% versus … Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left.
Categories: Antineoplastic and Immunomodulating AgentsrhThrombin
go.drugbank.com/drugs/DB04923ApprovedWithdrawnThe production of recombinant proteins is not dependent on the availability of blood from animals or human donors and can be scaled-up to meet market demand. … rhThrombin (recombinant human thrombin) is being developed by ZymoGenetics, Inc. as a general aid to achieving hemostasis during surgery.
Auranofin
go.drugbank.com/drugs/DB00995ApprovedInvestigationalHeme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties. … Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity.
Categories: Antiinflammatory and Antirheumatic ProductsTetraferric tricitrate decahydrate
go.drugbank.com/drugs/DB14520ApprovedInvestigationalTetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. … [A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926]
Mixtures: Maxine Vitamin and Mineral SupplementCategories: Drugs for Treatment of Hyperkalemia and HyperphosphatemiaSuvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Categories: Hypnotics and Sedatives, Miscellaneous Anxiolytics Sedatives and Hypnotics